SERUM AMYLOID-P COMPONENT IN CHRONIC-RENAL-FAILURE AND DIALYSIS

被引:80
作者
NELSON, SR
TENNENT, GA
SETHI, D
GOWER, PE
BALLARDIE, FW
AMATAYAKULCHANTLER, S
PEPYS, MB
机构
[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,DU CANE RD,LONDON W12 0NN,ENGLAND
[2] CHARING CROSS HOSP,DEPT MED,RENAL UNIT,LONDON W6 8RP,ENGLAND
[3] MANCHESTER ROYAL INFIRM,DEPT RENAL MED,MANCHESTER M13 9WL,LANCS,ENGLAND
[4] UNIV OXFORD,DEPT BIOCHEM,OXFORD,ENGLAND
关键词
SERUM AMYLOID-P COMPONENT; AMYLOIDOSIS; RENAL FAILURE; HEMODIALYSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS;
D O I
10.1016/0009-8981(91)90090-Y
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A normal reference interval for serum amyloid P component (SAP) concentration in the serum was established in 500 healthy adult individuals (274 women, 226 men), by electroimmunoassay calibrated with standards of highly purified, isolated SAP. The mass of SAP in these was determined from the extinction coefficient of SAP at 280 nm measured here precisely for the first time by spectrophotometry and cryogenic drying. The mean (SD, range) SAP concentration was significantly lower in women: 24 mg/l (8, 8-55), compared to 32 mg/l (7, 12-50) in men (P < 0.001). In renal insufficiency patients, 38 with chronic renal failure, 79 on hemodialysis and 66 on continuous ambulatory peritoneal dialysis, the mean values for SAP concentration were all significantly higher than normal (range of means, 39-59 mg/l in men and 35-42 mg/l in women), but did not correlate with serum creatinine, duration of dialysis or the presence of an acute phase response. The metabolism of SAP is thus altered in renal failure and is not normalized by dialysis, but it is not clear whether this is relevant to the pathogenesis of dialysis related arthropathy and amyloidosis.
引用
收藏
页码:191 / 199
页数:9
相关论文
共 29 条
[1]   CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS DOES NOT PREVENT THE DEVELOPMENT OF DIALYSIS-ASSOCIATED AMYLOIDOSIS [J].
ALONSO, JLM ;
CRUZ, A ;
REVUELTA, KL ;
CAPARROS, G ;
GONZALES, T ;
MUNOZ, J ;
MARTINEZ, ME ;
SELGAS, R .
NEPHRON, 1989, 53 (04) :389-390
[2]  
BALTZ ML, 1980, CLIN EXP IMMUNOL, V39, P355
[3]  
BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691
[4]   SERUM AMYLOID-P COMPONENT BINDS TO CELL-NUCLEI INVITRO AND TO INVIVO DEPOSITS OF EXTRACELLULAR CHROMATIN IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BREATHNACH, SM ;
KOFLER, H ;
SEPP, N ;
ASHWORTH, J ;
WOODROW, D ;
PEPYS, MB ;
HINTNER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (04) :1433-1438
[5]   PENTRAXIN-CHROMATIN INTERACTIONS - SERUM AMYLOID-P COMPONENT SPECIFICALLY DISPLACES H1-TYPE HISTONES AND SOLUBILIZES NATIVE LONG CHROMATIN [J].
BUTLER, PJG ;
TENNENT, GA ;
PEPYS, MB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (01) :13-18
[6]  
CATHCART ES, 1967, P SOC EXP BIOL MED, V125, P1123
[7]   ISOLATION OF HUMAN C-REACTIVE PROTEIN AND SERUM AMYLOID P COMPONENT [J].
DEBEER, FC ;
PEPYS, MB .
JOURNAL OF IMMUNOLOGICAL METHODS, 1982, 50 (01) :17-31
[8]  
DESTRIHOU CV, 1988, ADV NEPHROL, V17, P401
[9]  
Dubin S B, 1972, Methods Enzymol, V26, P119
[10]   CONFIDENCE-INTERVALS RATHER THAN P-VALUES - ESTIMATION RATHER THAN HYPOTHESIS-TESTING [J].
GARDNER, MJ ;
ALTMAN, DG .
BMJ-BRITISH MEDICAL JOURNAL, 1986, 292 (6522) :746-750